

The DARPin[®] Difference: Offering Patients a New Dimension of Protein Therapeutics



R&D Day
Speaker Bios



MOLECULAR
partners



Patrick Amstutz, PhD

Chief Executive Officer



Dr. Patrick Amstutz became Chief Executive Officer of Molecular Partners in November 2016. From 2014 to 2016, he was the Company's Chief Operating Officer and from 2006 to 2014, Chief Business Officer. A co-founder of Molecular Partners, he has been a member of the Company's management team since its inception in 2004. As Chief Operating Officer and Chief Business Officer, Dr. Amstutz was responsible for business development, alliance management and research and development (R&D) operations. He has established a wide range of commercial collaborations and licensed several key technologies. Dr. Amstutz holds a Master of Science from the ETH Zurich (also known as the Swiss Federal Institute of Technology) and a PhD in Molecular Biology from the University of Zurich.



Andreas Harstrick, MD
Chief Medical Officer



Dr. Andreas Harstrick has been Chief Medical Officer of Molecular Partners since 2015. He received his MD degree from the University of Hannover in 1986. After spending 12 years in academic medicine at the University of Hannover and the West German Cancer Center in Essen, he moved to the pharmaceutical industry in 1998. He held the position of Senior Vice President (SVP) of Oncology Development at Merck Serono from 1998 to 2008. In this function, he had the medical responsibility for all investigational compounds in oncology, as well as medical oversight for the Erbitux (cetuximab) clinical development and registration programs in all territories outside of North America. From 2008 to 2014, he was SVP of Development and Medical Sciences at Imclone, where he was responsible for the design and conduct of all Imclone clinical trials, including the design and successful completion of the Phase 3 programs for Cyramza (ramucirumab) and Portrazza (necitumumab). In addition, Dr. Harstrick was a member of the Imclone/Lilly oncology development board and leader of the Lilly Erbitux team.



Prof. Angelo Vacca, MD
Chief of Internal Medicine



Dr. Angelo Vacca is Chief of Internal Medicine at the University of Bari Medical School in Bari, Italy, and also serves as the school's Vice-Rector and full professor. He also heads the school's Angiogenesis, Vascular Biology, and Myeloma Microenvironment Laboratory. In addition to his academic posts, Dr. Vacca is the honorary President of the Italian Society of Immunology, Clinical Immunology and Allergology. He completed his post-doctoral fellowship in clinical immunology at the University of Bari, and was awarded his M.D. degree in 1980. In 1983, Dr. Vacca began to specialize in hematology, and in 1993, in internal medicine. He spent three years at the Ludwig Institute for Cancer Research in Lausanne, Switzerland, focusing on the production of monoclonal antibodies, as well as on immunoscintigraphy and vascular access to human lymphomas. Currently, his research efforts focus on angiogenesis and tumor progression (including the study of tumor microvasculature as a progression marker; correlation with invasion and metastasis; bone marrow angiogenesis and myeloma progression; mechanisms of induction of angiogenesis), as well as on multiple myeloma and related malignancies (including clinical, cellular and immunochemical features; polycenter, controlled chemotherapy studies). Dr. Vacca has published over 300 papers in international medical journals and has authored numerous reviews and book chapters. He has also received the Associazione Italiana per la Ricerca sul Cancro (Milan, Italy) Award for his research.



Prof. Kathryn A. Gold, MD

Associate Professor of Medicine, Division of Hematology and Oncology

UC San Diego
MOORES CANCER CENTER

Dr. Gold is an Associate Professor of Medicine in the Division of Hematology and Oncology at the University of California San Diego Moores Cancer Center. She is the Associate Director of Clinical Research Services at the Altman Clinical and Translational Research Institute and the chair of the Moores Cancer Center Data and Safety Monitoring Committee. Dr. Gold is an active clinical and translational researcher, with a focus on the use of targeted therapies for the treatment of lung and head and neck cancers, in addition to running a successful clinical practice. Dr. Gold's research has appeared in the *New England Journal of Medicine*, *Science*, and the *Journal of Clinical Oncology*, and has been presented at national and international meetings. She served as the principal investigator of numerous of pharmaceutical industry-sponsored and investigator-initiated studies, and has received grant support from the National Institutes of Health and the American Society of Clinical Oncology Conquer Cancer Foundation.



Richard Baird, MA, MBBS, FRCP, PhD
Academic Consultant, Experimental Cancer Therapeutics



UNIVERSITY OF
CAMBRIDGE

Dr. Baird is an Academic Consultant in Experimental Cancer Therapeutics at the University of Cambridge, UK. He is also a cancer researcher and medical oncologist at Cambridge University Hospitals. He trained at the University of Cambridge and the Institute of Cancer Research/Royal Marsden Hospital. Dr. Baird holds a Ph.D. in molecular pharmacology and cancer drug development and specializes in the care of breast cancer patients. Dr. Baird's research focuses on the development of novel HER2-targeted therapies, including better approaches for patients with brain metastases, as well as companion biomarkers to identify patients most likely to respond to treatment (or not) – including liquid biopsies/circulating tumor DNA. Since 2002 he has served as co- or principal investigator on more than 80 Phase 1/2 clinical trials, and is currently the chief investigator on three multi-center, investigator-initiated clinical trials. He is the UK national academic lead for the Association of Cancer Physicians.



Michael Stumpp, PhD
Chief Scientific Officer



Dr. Michael Tobias Stumpp is Chief Scientific Officer of Molecular Partners, where he oversees internal research and development (R&D) activities including the Company's internal pipeline. A co-founder of Molecular Partners, Dr. Stumpp is a co-developer of the Company's DARPin® technology, for which he received his PhD from the University of Zurich. He started his scientific career at the ETH Zurich (also known as the Swiss Federal Institute of Technology) and then progressed to Imperial College London and the Tokyo Institute of Technology. Dr. Stumpp has published his research in several international peer-reviewed scientific journals and has presented his findings at numerous congresses.



Baldo Scassellati Sforzolini, MD, PhD, MBA
Senior Vice President, Clinical Development



Dr. Baldo Scassellati Sforzolini is Senior Vice President, Clinical Development at Allergan. Previously, he was Vice President, Global Development at Bausch + Lomb and Vice President, Ophthalmology Development at Novartis. He has also held positions of increased responsibilities at Pfizer and Pharmacia.

Dr. Scassellati Sforzolini holds an MD degree from the University of Bologna, a PhD in Neurosensory Science and Ophthalmology Residency from the University of Ancona, a Diploma of Pharmaceutical Medicine from Cardiff University, and an MBA from Cranfield School of Management.